We are not a broad-line company. Each area below is one where existing treatment leaves a gap we can address with our own chemistry and our own manufacturing discipline.
Chronic cardiovascular disease asks for medicines taken for decades, so our cardiology work starts with tolerability and drug-drug interaction risk rather than raw potency.
What we focus on
Antimicrobial resistance is a moving target. We build compounds with narrow, well-characterised spectra and resistance barriers that are documented before a programme advances.
What we focus on
Our oncology portfolio is deliberately small: precision biologics for solid tumours where the biology is well defined and the therapeutic window is genuinely wider than today's options.
What we focus on
We only enter indications where the endpoint that matters to patients can be measured within a realistic trial horizon.
Every programme carries a pre-registered readout that can stop it. Ambiguity is treated as a finding, not a delay.
Synthesis and formulation are reviewed in the same gate review as the science, so a promising candidate is never stranded by its own process.